Efficacy of 0.25% timolol gel in healing surgical open wounds: A randomized clinical trial - 18/12/25
Doi : 10.1016/j.jaad.2025.09.063
Nancy Anabaraonye, BA, Nina Ran, MD, MS, Emily E. Karn, MS, Fadi Murad, BSc, MD, MPH, David Stein, PhD, Emily Ruiz, MD, MPH, Chrysalyne Schmults, MD, MSCE, Abigail Waldman, MD ⁎ 
Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
∗Correspondence to: Abigail Waldman, MD, Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, 1153 Centre St Suite 4J, Boston, MA 02130Department of DermatologyBrigham and Women's HospitalHarvard Medical School1153 Centre St Suite 4JBostonMA02130
Key words : dermatology, Mohs surgery, timolol, topical beta-blocker, wound healing
| Author Anabaraonye and Dr Ran are co-first authors. |
|
| Funding sources: None. |
|
| Patient consent: Not applicable. |
|
| IRB approval status: Approval # 2024P001422. |
© 2025
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 94 - N° 1
P. 208-210 - janvier 2026 Retour au numéro
Article précédent
- Low-dose naltrexone for treatment of dermatologic conditions: A clinical review
- Maggie H. Zhou, Dirk M. Elston, Brian W. Morrison, Shari R. Lipner
- Inpatient management of hidradenitis suppurativa: A single-center retrospective study
- Narges Maskan Bermudez, Marita Yaghi, Scott A. Elman, Robert S. Kirsner, Hadar Lev-Tov
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?